anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Budesonide
Trial phase: Phase 3
ATC code: A07EA06 | D07AC09 | R01AD05 | R03AK07 | R03AK12 | R03AL11 | R03BA02
SMILES: CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C)C4C(O)CC3(C)C2(C(=O)CO)O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 134
Group description: Participants who were diagnosed with active mild to moderate UP or UPS, received 2 mg/25 mL of budesonide foam, rectally twice daily for a period of 2 weeks followed by 2 mg/25 mL of budesonide foam, rectally once daily for a period of 4 weeks.
Eligibility criteria:
Inclusion Criteria:

Voluntarily sign written informed consent.
Male or non-pregnant and non-lactating females.
Confirmed diagnosis (by endoscopy procedure) of active, mild to moderate UP or UPS, with disease extending at least 5 centimeters (cm) but no further than 40 cm from the anal verge.
Must possess a baseline MMDAI score between 5 and 10.

Exclusion Criteria:

History or current diagnosis of Crohn's disease and indeterminate colitis.
Prior gastrointestinal surgery except appendectomy and hernia.
Concomitant active gastrointestinal disease or distortion of intestinal anatomy.
History of diverticulitis, collagenous colitis, celiac disease, recurrent pancreatic or known gallbladder disease.
Uncontrolled, previously diagnosed type 1 or 2 diabetes mellitus.
Uncontrolled abnormal thyroid function.
Unstable significant cardiovascular, endocrine, neurologic or pulmonary disease.
Hemoglobin levels less than (<) 7.5 grams /deciliter (g/dL).
History of sclerosing cholangitis, cirrhosis, or hepatic impairment.
Renal disease manifested by greater than (>) 2.0 milligrams/deciliter (mg/dL) serum creatinine.
History of avascular hip necrosis, active tuberculosis, ocular herpes simplex or ocular varicella zoster, malignant disease, and HIV or hepatitis B or C.
Adrenal insufficiency.
Active systemic or cutaneous infection or toxic megacolon, fistula, perforation or abscess.
History of uncontrolled psychiatric disorders or seizure disorders.
History of asthma requiring ongoing use of inhaled steroids.
Recent history of drug or alcohol abuse.
Positive stool test for bacterial pathogens, Clostridium difficile toxin, or ovum and parasites.
Vaccination within 28 days prior to randomization.
Allergies to budesonide or to any other items used in its preparation.
Participation in another clinical trial in the past 30 days.
Pregnant or at risk of pregnancy.
Taking a prohibited medication. Some medications to treat UP/UPS are prohibited during participation in the study, including laxatives and anti-diarrhea medications; however, oral 5-ASA agents at doses up to 4.8 g/day and daily fiber supplements are allowed. Other medications (e.g., antibiotics, anti-seizure and anti-coagulant medicines) are also prohibited.
Intervention: MAGNESIUM OXIDE
Trial phase: Phase 2
ATC code: A02AA02 | A06AD02 | A12CC10
SMILES: O=[Mg]
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 29
Group description: Patients receive magnesium oxide PO QD or BID for 4 weeks.
Eligibility criteria:
DISEASE CHARACTERISTICS:

Meets 1 of the following criteria:

History of breast cancer (currently without malignant disease)
No history of breast cancer but wishes to avoid estrogen due to a perceived increased risk of breast cancer
Must have bothersome hot flashes (defined by their occurrence of ≥ 14 times per week and of sufficient severity to make the patient desire therapeutic intervention) for ≥ 1 month before study entry
Has undergone treatment for cancer (patients other than breast cancer survivors are eligible)

PATIENT CHARACTERISTICS:

Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
Creatinine clearance ≥ 30 mL/min
No hypersensitivity to magnesium oxide
No medical or other condition(s) that, in the opinion of the investigator/sub-investigator, may compromise the objectives of the study

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
More than 4 weeks since prior and no concurrent antineoplastic chemotherapy, androgens, estrogens, progestational agents, or gabapentin
More than 28 days since prior and no other concurrent investigational drugs
Concurrent tamoxifen, raloxifene, or aromatase inhibitors allowed provided patient has been on a constant dose for > 4 weeks AND is not expected to stop the medication during the study period
Intervention: Aripiprazole
Trial phase: Phase 3
ATC code: N05AX12
SMILES: O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 114
Group description: Aripiprazole administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4; 10 mg on Days 5, 6 and 7; and then administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.
Eligibility criteria:
Inclusion Criteria:

Participants must currently meet the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for schizophrenia and have experienced symptoms of the illness for at least 1 year, and they should have had at least treatment with 1 antipsychotic before participation in this study
Participants having a Positive and Negative Syndromes Scale (PANSS) score between 60 and 120 inclusive at Screening
Female participants must be incapable of pregnancy, or if heterosexually active and capable of pregnancy, have been using an acceptable method of contraception for at least 1 month before study entry and agree to continue use contraception methods for the duration of the study, or if sexually abstinent (not having sexual intercourse) and capable of pregnancy, must agree to continue abstinence or to use an acceptable method of birth control
Participants must not be a danger to themselves or others, and must have family support available to be maintained as out-patients
Participants with a weight of equal to or greater than 29 kilogram

Exclusion Criteria:

Participants with mild (not serious), moderate (medium level of seriousness), or severe (very serious, life threatening) mental retardation
Participants with a known or suspected history of substance dependence (including alcohol, but excluding nicotine or caffeine) as per the DSM-IV criteria in the 3 months before Screening
Participants with a history of certain neurological (pertaining to the nervous system) disorders or insulin-dependent diabetes mellitus (disorder in which there is decreased insulin in the body or the body's insulin is not effective, resulting in high blood sugar, increased thirst and urine, and many other side effects)
Participants who have received a depot injectable antipsychotic within 2 treatment cycles before the Screening visit
Participants who have received clozapine in 2 months before the Baseline visit (Day 1 of Week 1)
Intervention: Azithromycin
Trial phase: Phase 4
ATC code: J01FA10 | J01RA07 | J01RA16 | S01AA26
SMILES: CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)CN(C)C(C)C(O)C1(C)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 40
Group description: 250 mg daily for 5 days, followed by 250 mg three times a week (Mon.-Wed.-Fri.) until the end of study
Eligibility criteria:
Inclusion Criteria:

Stable LTx recipients at discharge after transplantation.
Signed informed consent
Adult (age at least 18 years old at moment of transplantation)
Able to take oral medication

Exclusion Criteria:

Prolonged and/or complicated ICU-course after transplantation.
Early (<30 days post-transplant) post-operative death
Major suture problems (airway stenosis or stent)
Retransplantation (lung)
Previous transplantation (solid organ)
Multi-organ transplantation (lung+ other solid organ)
Intervention: Chlorambucil
Trial phase: Phase 3
ATC code: L01AA02
SMILES: O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 116
Group description: Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
Eligibility criteria:
Inclusion Criteria:

Adults >/=18 years
Documented Cluster of Differentiation Antigen 20 (CD20) + B-Cell Chronic Lymphocytic Lymphoma (B-CLL)
Previously untreated Chronic Lymphocytic Leukemia (CLL) requiring treatment according to the National Cancer Institute (NCI) criteria
Total Cumulative Illness Rating Scale (CIRS) > 6 and/or creatinine clearance < 70 ml/min

Exclusion Criteria:

Prior CLL therapy
Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
History of other malignancy unless the malignancy has been in remission without treatment for >/=2 years prior to enrolment, and except for carcinoma in situ of the cervix, basal or squamous cell skin cancer, surgically treated low-grade prostate cancer, or ductal carcinoma in situ (DCIS) of the breast treated with lymphectomy alone
Positive hepatitis serology (HBV, HCV) or positive HIV or Human T Cell Leukemia Virus (HTLV) testing
Patients with active infection requiring systemic treatment
Intervention: Vaniprevir
Trial phase: Phase 1
SMILES: [H][C@@]1(C(=O)N[C@]2(C(=O)NS(=O)(=O)C3CC3)C[C@H]2CC)C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)OCC(C)(C)CCCCc1cccc3c1CN(C3)C(=O)O2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: Participants with mild hepatic insufficiency (HI) administered a single 300 mg oral tablet of vaniprevir
Eligibility criteria:
Inclusion Criteria:

Hepatic Participants:

Females of reproductive potential test negative for pregnancy and agree to use an appropriate method of contraception during the study
Apart from hepatic insufficiency, is in good general health
Has a diagnosis of chronic stable hepatic insufficiency
Score on the Child-Pugh scale ranged from 5 to 6 (mild hepatic insufficiency); from 7 to 9 (moderate hepatic insufficiency); from 10 to 15 (severe hepatic insufficiency). Moderate and Severe participants must have had a 50% score of 2 or higher on at least one of the laboratory parameters (i.e., albumin, prothrombin time, bilirubin) at the prestudy visit.

Healthy Matched Participants:

Females of reproductive potential test negative for pregnancy and agree to use an appropriate method of contraception during the study
Is in good health

Exclusion Criteria:

Female is pregnant, lactating, expecting to become pregnant or donate eggs
Has a history of stroke or seizures
Has a history of cancer
Is unable to refrain from the use of any prescription or non-prescription medication
Consumes excessive amounts of alcohol or caffeinated beverages daily
Has had surgery, donated blood or participated in another investigational study with in the last 4 weeks
Is a regular user or past abuser of any illicit drug including alcohol
Intervention: Vaniprevir
Trial phase: Phase 1
SMILES: [H][C@@]1(C(=O)N[C@]2(C(=O)NS(=O)(=O)C3CC3)C[C@H]2CC)C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)OCC(C)(C)CCCCc1cccc3c1CN(C3)C(=O)O2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: Participants with moderate HI administered a single 300 mg oral tablet of vaniprevir
Eligibility criteria:
Inclusion Criteria:

Hepatic Participants:

Females of reproductive potential test negative for pregnancy and agree to use an appropriate method of contraception during the study
Apart from hepatic insufficiency, is in good general health
Has a diagnosis of chronic stable hepatic insufficiency
Score on the Child-Pugh scale ranged from 5 to 6 (mild hepatic insufficiency); from 7 to 9 (moderate hepatic insufficiency); from 10 to 15 (severe hepatic insufficiency). Moderate and Severe participants must have had a 50% score of 2 or higher on at least one of the laboratory parameters (i.e., albumin, prothrombin time, bilirubin) at the prestudy visit.

Healthy Matched Participants:

Females of reproductive potential test negative for pregnancy and agree to use an appropriate method of contraception during the study
Is in good health

Exclusion Criteria:

Female is pregnant, lactating, expecting to become pregnant or donate eggs
Has a history of stroke or seizures
Has a history of cancer
Is unable to refrain from the use of any prescription or non-prescription medication
Consumes excessive amounts of alcohol or caffeinated beverages daily
Has had surgery, donated blood or participated in another investigational study with in the last 4 weeks
Is a regular user or past abuser of any illicit drug including alcohol
Intervention: Vaniprevir
Trial phase: Phase 1
SMILES: [H][C@@]1(C(=O)N[C@]2(C(=O)NS(=O)(=O)C3CC3)C[C@H]2CC)C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)OCC(C)(C)CCCCc1cccc3c1CN(C3)C(=O)O2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: Participants with severe HI administered a single 200 mg oral tablet of vaniprevir
Eligibility criteria:
Inclusion Criteria:

Hepatic Participants:

Females of reproductive potential test negative for pregnancy and agree to use an appropriate method of contraception during the study
Apart from hepatic insufficiency, is in good general health
Has a diagnosis of chronic stable hepatic insufficiency
Score on the Child-Pugh scale ranged from 5 to 6 (mild hepatic insufficiency); from 7 to 9 (moderate hepatic insufficiency); from 10 to 15 (severe hepatic insufficiency). Moderate and Severe participants must have had a 50% score of 2 or higher on at least one of the laboratory parameters (i.e., albumin, prothrombin time, bilirubin) at the prestudy visit.

Healthy Matched Participants:

Females of reproductive potential test negative for pregnancy and agree to use an appropriate method of contraception during the study
Is in good health

Exclusion Criteria:

Female is pregnant, lactating, expecting to become pregnant or donate eggs
Has a history of stroke or seizures
Has a history of cancer
Is unable to refrain from the use of any prescription or non-prescription medication
Consumes excessive amounts of alcohol or caffeinated beverages daily
Has had surgery, donated blood or participated in another investigational study with in the last 4 weeks
Is a regular user or past abuser of any illicit drug including alcohol
Intervention: Ketorolac
Trial phase: Phase 4
ATC code: M01AB15 | S01BC05 | S01FB51
SMILES: O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 60
Group description: Ketorolac 30 mg, administered intravenously over 15 minutes
Eligibility criteria:
Inclusion Criteria:

Acute tension type headache

Exclusion Criteria:

Contraindications to investigational medications
Secondary cause of headache
Intervention: Metoclopramide
Trial phase: Phase 4
ATC code: A03FA01
SMILES: CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 60
Group description: metoclopramide 20 mg + diphenhydramine 25 mg, administered intravenously over 15 minutes
Eligibility criteria:
Inclusion Criteria:

Acute tension type headache

Exclusion Criteria:

Contraindications to investigational medications
Secondary cause of headache
Intervention: Varenicline
Trial phase: Not Applicable
ATC code: N07BA03 | S01XA28
SMILES: c1cnc2cc3c(cc2n1)C1CNCC3C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 33
Group description: Drug: varenicline (Chantix) 12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).

varenicline : 12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).
Eligibility criteria:
Inclusion Criteria:

Age between 21 and 75 years.
Currently seeking treatment for nicotine dependence (smoke at least 10 cigarettes daily) and found to have problem drinking, alcohol abuse or alcohol dependence (non-physiological) as determined by amount of alcohol consumed weekly (Average weekly alcohol consumption (last 30 days), >7 standard drinks (for women) or >14 standard drinks (for men), clinical interview, and AUDIT score > 8.
Generally healthy, without serious or unstable medical/mental illness(es).
Smokers only will be included (degree of nicotine dependence will be assessed and included in analysis).
Able to give voluntary, written, informed consent

Exclusion Criteria:

More than 30 days of abstinence from alcohol in the prior 90 days.
History of major alcohol-related complications within the preceding 2 years (liver failure/cirrhosis, pancreatitis, esophageal varices, liver function tests > 3 X ULN).
Intolerance to the study medication.
Current psychiatric disorder(s) requiring clinical treatment.
Any recent history (i.e. within the preceding 5 years) of suicide attempt or current suicidal ideation.
Use of illicit or non-prescribed psychotropic drug use (opiates, benzodiazepines, cocaine, PCP, methamphetamine, cocaine, or marijuana more than twice a week).
A history of complicated alcohol or other drug withdrawal syndrome(s), e.g.: delirium tremens or seizures.
Intervention: Sufentanil
Trial phase: Phase 1 | Phase 2
ATC code: N01AH03
SMILES: CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 16
Group description: Patients with a suspected acute bony injury to an extremity and in moderate to severe pain
Eligibility criteria:
Inclusion Criteria:

18 years old or older;
isolated traumatic injury to upper or lower extremity;
alert and oriented to name, date, place; patient has a numeric pain score of 5 or higher;
speaks English as their primary language;
female patients are on birth control, menopausal, or are sterile (hysterectomy, tubal ligation)

Exclusion Criteria:

injury isolated to a finger or toe;
previous nasal or sinus surgery; chronic nasal problem;
acute nasal problem (ie epistaxis, upper respiratory infection, sinusitis);
pregnant; prisoner; allergy to sufentanil, fentanyl, or alfentanil; history of analgesic abuse or dependency;
presence of other painful injuries; systolic Blood Pressure less than 100 mm Hg;
patient seems or is confused or has a head injury; room air oxygenation less than 95%;
patient has chronic obstructive pulmonary disease, severe asthma, oxygen-dependent pulmonary disease;
impaired hepatic or renal function (obtained clinically or by history);
weight more than 230 lbs (100 kg);
alcohol or drug intoxication (per patient admission or clinical assessment of physician);
elderly (> 70 years)
Intervention: Atorvastatin
Trial phase: Phase 2
ATC code: C10AA05 | C10BA05 | C10BX03 | C10BX06 | C10BX08 | C10BX11 | C10BX12 | C10BX15 | C10BX18 | C10BX19
SMILES: CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 28
Group description: 1:1 randomization will be used to assign half of enrolled subjects to the treatment arm. These subjects will receive a daily weight-based dose of atorvastatin 1mg/kg (up to 80 mg) for 7 days starting within 24 hours of mTBI, and their outcome will be compared with the group of subjects receiving a placebo.
Eligibility criteria:
Inclusion Criteria:

age 18-50 years
MTBI subjects: evidence of closed head injury; Glasgow Coma Score 13-15; loss of consciousness < 30 minutes; post-traumatic amnesia < 24 hours; Abbreviated Injury Score </= 3 for any body region; absence of focal lesions on head CT scan
Orthopedic Injury subjects: evidence of traumatic injury, other than head; Abbreviated Injury Score </= 3 for any body region
does not require hospitalization for injuries
visual acuity and hearing adequate to participate in testing
fluent in either English or Spanish

Exclusion Criteria:

Abbreviated Injury Score > 3 for any body region
any type of penetrating injury
history of significant pre-existing disease or systemic injuries
history of schizophrenia or bipolar disorder
blood alcohol > 200 mL/dL
left-handed
existing contraindications for MRI
claustrophobia
pregnancy
exclusions related to atorvastatin, including currently taking any statin drug (atorvastatin, simvastatin, rosuvastatin, pravastatin, lovastatin, fluvastatin), no longer taking a statin drug but history of use within the last six months, previously taking any statin drug at any time but now discontinued due to side effects, taking any medication with known interactions with atorvastatin (cyclosporine, fibric acid derivative, erythromycin, clarithromycin, combination of ritonavir plus saquinavir or lopinavir, niacin in doses exceeding multivitamin dosage, or azole antifungals), active liver disease, history of unexplained persistent elevation of serum transaminases, and hypersensitivity to any component of atorvastatin.
Intervention: Lovenox
Trial phase: Phase 1
SMILES: CC(=O)NC1C(O)OC(COS(=O)(=O)O)C(OC2OC(C(=O)O)C(OC3OC(CO)C(OC4OC(C(=O)O)C(O)C(O)C4OS(=O)(=O)O)C(OS(=O)(=O)O)C3NS(=O)(=O)O)C(O)C2OS(=O)(=O)O)C1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 62
Group description: Enoxaparin started at 24 hours post-injury and continued until 96 hours post-injury.

enoxaparin: Enoxaparin 30 mg sq q 12 hours
Eligibility criteria:
Inclusion Criteria:

1. Male and female patients admitted to the ETMC SICU with TBI who speak English or Spanish.

Exclusion Criteria:

Epidural or subdural hematoma > 8mm.
Intraparenchymal contusion >2 cm
Multiple contusions w/in one lobe
Subarachnoid hemorrhage in basilar or supracellar cistern and positive CTA
Increased TBI on 24 hr post-injury CT
Spinal canal hematoma
Nonoperative mgmt of American Association for the Surgery of Trauma (AAST) Grade IV or higher organ injury
Gastrointestinal hemorrhage
Ongoing bleeding from a pelvic fracture
Anticipated open reduction of long bone or pelvic fracture within study period.
Intracranial pressure (ICP) >20 mmHg
Coagulopathy consisting of International Normalized Ratio (INR)>1.5 or platelet count <50,000
Expect brain death/discharge in 48 hrs
Pre-existing dialysis dependence
Documented DVT at time of admission
Prisoners
Pregnancy
Age <18 years
Terminally ill patients
Anticoagulant use at time of injury
Inability to gain consent from patient or legal next-of-kin in instance of TBI, intoxication, or psychiatric diagnoses
Documented history of heparin allergy
Initial head CT >6 hours post-injury
Intervention: Propofol
Trial phase: Not Applicable
ATC code: N01AX10
SMILES: CC(C)c1cccc(C(C)C)c1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 33
Group description: After induction, the intravenous anesthesia group received an infusion of propofol (100-200 μg/kg/min) for endoscopic sinus surgery.
Eligibility criteria:
Inclusion Criteria:

male or female patients who are 18 years of age or older,
ASA grade 1 (normal otherwise healthy patient),
ASA grade 2 (patient with mild systemic disease),
patients who have chronic sinusitis with or without nasal polyps.

Exclusion Criteria:

pregnancy,
abnormal coagulation panel
preoperative use of NSAIDS or ASA medications within 7 days,
end-stage renal disease,
allergy to any of the used medications,
maximal body mass index over 35
Intervention: Sevoflurane
Trial phase: Not Applicable
ATC code: N01AB08
SMILES: FCOC(C(F)(F)F)C(F)(F)F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 33
Group description: After induction, the inhalation anesthesia group received sevoflurane (1% to 3%) for endoscopic sinus surgery.
Eligibility criteria:
Inclusion Criteria:

male or female patients who are 18 years of age or older,
ASA grade 1 (normal otherwise healthy patient),
ASA grade 2 (patient with mild systemic disease),
patients who have chronic sinusitis with or without nasal polyps.

Exclusion Criteria:

pregnancy,
abnormal coagulation panel
preoperative use of NSAIDS or ASA medications within 7 days,
end-stage renal disease,
allergy to any of the used medications,
maximal body mass index over 35